Port delivery system: a novel drug delivery platform to treat retinal diseases

References

• Huang X, Chau Y. Intravitreal nanoparticles for retinal delivery. Drug Discov Today. 2019 Aug;24(8):1510–1523.
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Lutz D, Shen J, et al. Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation. Pharm Res. 2018 Oct 29;35(12):245.
   PubMed Web of Science ®Google Scholar
• Platania CB, Di Paola L, Leggio GM, et al. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol. 2015 Oct 29;6:248.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013 Jul;27(7):787–794.
   PubMed Web of Science ®Google Scholar
• Kiss S, Dugel PU, Khanani AM, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018;12:1625–1635.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015 Feb;99(2):220–226.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the united states. Ophthalmol Retina. 2020 Feb;4(2):122–133.
   PubMedGoogle Scholar
• Ozturk M, Harris ML, Nguyen V, et al. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol. 2018 May;46(4):407–411.
   PubMed Web of Science ®Google Scholar
• Rao P, Lum F, Wood K, et al. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2018 Apr;125(4):522–528.
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020 Jan;104(1):39–46.
   PubMed Web of Science ®Google Scholar
• Genetech. Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration. 2020. [cited 1 Jun 2020]. gene.com
   Google Scholar
• Cimberle M. Strategies for sustained anti-VEGF delivery aimed at consistent dosing, durability. Helio News. 2020. [cited 1 Jun 2020]. Helio.com
   Google Scholar
• Campochiaro Pa, Marcus DM, Awh CC, et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019 Aug;126(8):1141–1154.
   PubMed Web of Science ®Google Scholar
• Kirkner RM. PDS with ranibizumab: it’s in the technique. Retina Specialist. 2020;6(5):37-38.
   Google Scholar
• Pieramici DJ. The Port Delivery System With Ranibizumab. Retin Physician. Mar 2019;16:46-49.
   Google Scholar
• Loewenstein A, Laganovska G, Bressler NM, et al. Phase 1 Clinical Study of the Port Delivery System with ranibizumab for continuous treatment of neovascular age-related macular degeneration. ARVO Annual Meeting: Investigative Ophthalmology & Visual Science. Jun 2020;61(7).
   Google Scholar
• Seminara L. Ranibizumab Port Delivery System for AMD: phase 2. EyeNet Magazine. 2019.
   Google Scholar
• Hopkins JJ, Regillo CD, Osborne A, et al. Sustained Delivery of Ranibizumab: the LADDER Trial of the Ranibizumab Port Delivery System. ARVO Annual Meeting: Investigative Ophthalmology & Visual Science. 2016.
   Google Scholar
• Khanani AM, Callanan D, Dreyer R, et al. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2020 Nov 18;5(8).
   Google Scholar
• Khanani AM, Gune S, Maia M, et al. Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial. In: 20th EURETINA Congress. Netherlands: Amsterdam, Noord Holland; 2020.
   Google Scholar
• Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration. Basel, Switzerland: GlobeNewswire 2020.
   Google Scholar
• Campochiaro PA. Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab for Patients With Neovascular AMD. American Society of Retina Specialists Annual Meeting. 2020.
   Google Scholar
• Khanani AM, Kuppermann BD, Weng CY. Breaking New Ground: reducing Treatment Burden in Neovascular AMD: new York Eye and Ear Infirmary of Mount Sinai. MedEdicus. 2020 November;1:2020.
   Google Scholar
• Bagheri N, Chiang A, Avery RL, et al. The AMD Pipeline: a Look at the Latest Results. Retina Today: Retina Today 2020.
   Google Scholar
• Pieramici DJ, Gune S, Maia M, et al. Pharmacokinetic Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Archway Trial. Macular Society. 2021.
   Google Scholar
• Mahler K, Highlights ASRS 2020. Roche Analyst Webcast; 2020; San Francisco; 2020.
   Google Scholar
• Roche H-L. Extension Study for the Port Delivery System With Ranibizumab (Portal). 2021. https://clinicaltrials.gov/ct2/show/NCT03683251
   Google Scholar
• Roche H-L. This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With 515 Intravitreal Ranibizumab (Pagoda). 2021. Available from: https:// clinicaltrials.gov/ct2/show/NCT04108156
   Google Scholar
• Roche H-L, Multicenter A. Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION). 2021. [cited 1 Jun 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT04503551
   Google Scholar
• Siddiqui FA, Aziz, AA, Khanani, AM. Gene Therapy for Neovascular AMD. Retin Physician. 2020 Feb 1;17:36–39. PentaVision, Inc. www.retinalphysician.com/issues/2020/special-edition-2020/gene-therapy-for-neovascular-amd
   Google Scholar